Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.
Bloom Burton & Co has announced changes in its holdings of Satellos Bioscience Inc. The firm acquired 1,692,250 common shares at $0.90 per share, totaling $1,523,025, through a public offering dated December 17, 2024. Despite this acquisition, Bloom Burton's beneficial holdings decreased by approximately 3.7% on a partially diluted basis.
Following the transaction, Bloom Burton, its affiliates, and Brian Bloom now own 10,400,818 shares and 7,528,732 derivative securities, representing approximately 6.3% ownership on a non-diluted basis and 10.3% on a partially diluted basis. Previously, they held 8,708,568 shares and 7,528,732 derivative securities, representing 7.6% non-diluted and 13.3% partially diluted ownership.
Bloom Burton & Co ha annunciato cambiamenti nelle sue partecipazioni in Satellos Bioscience Inc. La società ha acquisito 1.692.250 azioni ordinarie a 0,90 $ per azione, per un totale di 1.523.025 $, attraverso un'offerta pubblica datata 17 dicembre 2024. Nonostante questa acquisizione, le partecipazioni utili di Bloom Burton sono diminuite di circa il 3,7% su base parzialmente diluita.
In seguito alla transazione, Bloom Burton, le sue affiliate, e Brian Bloom possiedono ora 10.400.818 azioni e 7.528.732 titoli derivati, rappresentando circa il 6,3% di proprietà su base non diluita e il 10,3% su base parzialmente diluita. In precedenza, detenevano 8.708.568 azioni e 7.528.732 titoli derivati, rappresentando il 7,6% di proprietà non diluita e il 13,3% di proprietà parzialmente diluita.
Bloom Burton & Co ha anunciado cambios en sus participaciones de Satellos Bioscience Inc. La firma adquirió 1.692.250 acciones comunes a 0,90 $ por acción, totalizando 1.523.025 $, a través de una oferta pública fechada el 17 de diciembre de 2024. A pesar de esta adquisición, las participaciones beneficiosas de Bloom Burton disminuyeron aproximadamente un 3,7% en una base parcialmente diluida.
Después de la transacción, Bloom Burton, sus afiliados y Brian Bloom ahora poseen 10.400.818 acciones y 7.528.732 valores derivados, que representan aproximadamente un 6,3% de propiedad en una base no diluida y un 10,3% en una base parcialmente diluida. Anteriormente, poseían 8.708.568 acciones y 7.528.732 valores derivados, que representaban un 7,6% de propiedad no diluida y un 13,3% de propiedad parcialmente diluida.
Bloom Burton & Co는 Satellos Bioscience Inc의 보유 자산 변경을 발표했습니다. 이 회사는 2024년 12월 17일 자 공모를 통해 주당 0.90달러에 1,692,250주의 보통주를 인수하며, 총 1,523,025달러에 달합니다. 이러한 인수에도 불구하고 Bloom Burton의 유리 자산은 부분적으로 희석된 기준으로 약 3.7% 감소했습니다.
거래 후 Bloom Burton, 그 자회사 및 Brian Bloom은 이제 10,400,818주 및 7,528,732개의 파생상품을 보유하고 있으며, 이는 비희석 기준으로 약 6.3%, 부분적으로 희석된 기준으로 10.3%의 소유권을 나타냅니다. 이전에는 8,708,568주 및 7,528,732개의 파생상품을 보유하고 있었으며, 이는 비희석 기준으로 7.6%, 부분적으로 희석된 기준으로 13.3%의 소유권을 나타냅니다.
Bloom Burton & Co a annoncé des changements dans ses participations de Satellos Bioscience Inc. La société a acquis 1.692.250 actions ordinaires à 0,90 $ par action, pour un total de 1.523.025 $, par le biais d'une offre publique datée du 17 décembre 2024. Malgré cette acquisition, les participations bénéficiaires de Bloom Burton ont diminué d'environ 3,7 % sur une base partiellement diluée.
Suite à la transaction, Bloom Burton, ses affiliés et Brian Bloom détiennent désormais 10.400.818 actions et 7.528.732 titres dérivés, représentant environ 6,3 % de propriété sur une base non diluée et 10,3 % sur une base partiellement diluée. Auparavant, ils détenaient 8.708.568 actions et 7.528.732 titres dérivés, représentant 7,6 % de propriété non diluée et 13,3 % de propriété partiellement diluée.
Bloom Burton & Co hat Änderungen in seinem Besitz von Satellos Bioscience Inc angekündigt. Die Firma erwarb 1.692.250 Stammaktien zu je 0,90 $, was insgesamt 1.523.025 $ ergibt, im Rahmen eines öffentlichen Angebots vom 17. Dezember 2024. Trotz dieses Erwerbs reduzierte sich der wirtschaftliche Besitz von Bloom Burton um etwa 3,7 % auf einer teilweise verwässerten Basis.
Nach der Transaktion besitzen Bloom Burton, seine Tochtergesellschaften und Brian Bloom nun 10.400.818 Aktien und 7.528.732 derivative Wertpapiere, was etwa 6,3 % des Eigentums auf einer unverwässerten Basis und 10,3 % auf einer teilweise verwässerten Basis entspricht. Zuvor hielten sie 8.708.568 Aktien und 7.528.732 derivative Wertpapiere, was 7,6 % unverwässert und 13,3 % teilweise verwässert darstellt.
- Significant investment of $1.52M shows confidence in the company
- Decrease in beneficial holdings by 3.7% on partially diluted basis
- Reduction in ownership percentage from 7.6% to 6.3% on non-diluted basis
- Decline in partially diluted ownership from 13.3% to 10.3%
Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Bloom Burton & Co. Inc. (Bloom Burton) announces that, today, it acquired 1,692,250 common shares (Shares) of Satellos Bioscience Inc. (Corporation) in connection with a public offering of the Corporation by way of a prospectus supplement dated December 17, 2024 to the short form prospectus dated April 7, 2024. Bloom Burton purchased the Shares at a price of
Prior to this acquisition, Bloom Burton, its affiliates and Brian Bloom beneficially owned 8,708,568 Shares and 7,528,732 derivative securities (i.e., warrants, broker warrants, compensation options and stock options), representing approximately
The securities noted above are held for investment purposes. Bloom Burton has a long-term view of the investment and may acquire additional securities including either on the open market or through private acquisitions or sell the securities including either on the open market or through private dispositions in the future, depending on market conditions, reformulation of plans and/or other relevant factors.
The Corporation is located at Royal Bank Plaza, South Tower, 200 Bay Street, Suite 2800, Toronto, Ontario, M5J 2J1. A copy of the early warning report with respect to the foregoing will appear on the Corporation's profile on SEDAR at www.sedar.com and may also be obtained by contacting Jolyon Burton, Director, Bloom Burton at (416) 640-7575 or at info@bloomburton.com. Bloom Burton is a corporation existing under the laws of Ontario, specializing in the healthcare industry, with its head office at 181 Bay St., Suite 3410, Toronto, Ontario M5J 2T3.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/234822
FAQ
How many shares did Bloom Burton acquire in Satellos Bioscience in December 2024?
What is Bloom Burton's current ownership percentage in Satellos Bioscience?
How did Bloom Burton's ownership percentage change after the December 2024 transaction?
What is the total number of shares and derivative securities Bloom Burton owns in Satellos Bioscience?
